The former head of collapsed debenture firm Provident Capital has gotten court approval to appeal a ruling banning him from managing companies.
GlaxoSmithKline and Novartis have made another admission in a case brought by the ACCC alleging the drug giants made misleading claims in marketing their Voltaren Osteo Gel and Voltaren Emulgel pain relief products.
Class action firm Maurice Blackburn is calling for investors to join a lawsuit against Retail Food Group accusing the franchise giant of misleading the market about the long-term viability of its business model.
Volkswagen lost its bid Tuesday to exclude evidence from its own expert witness it claims has gone off script, an early blow to the car maker in the massive trial alleging it installed dual-mode software in diesel vehicles to cheat on emissions tests.
Reckitt Benckiser has filed an appeal against GlaxoSmithKline, after a judge found the consumer goods giant misled consumers with claims that Nurofen was a more effective pain killer than its rival’s Panadol and ordered it to pay all of GlaxoSmithKline’s legal bill.
Lawyers running a class action against Murray Goulburn want access to evidence that the dairy cooperative’s trust consulted with a QC about possible claims against its law firm, Herbert Smith Freehills.
A judge has called for a referee to look at Maurice Blackburn’s fees for running a shareholder class action against QBE Insurance that settled late last year for $133 million.
Reckitt Benckiser has brought a claim against its familiar courtroom foe – consumer goods giant Procter & Gamble – over a television commercial and in-store promotion it says violates the consumer laws.
A former Norton Rose employment partner in litigation with the firm over his firing has lost his bid to move next week’s scheduled mediation out of Sydney.
Pharmaceutical companies AstraZeneca and Generic Health have laid down their swords in a long-running patent dispute over AstraZeneca’s cholesterol drug Crestor, two-and-a-half years after the High Court of Australia found the patent obvious and invalid.